Association of Tef polymorphism with depression in Parkinson disease

Movement Disorders

Volumn 27, Issue 13, 2012, Pages 1694-1697

  Hua, Ping ^a   Liu, Weiguo ^a   Kuo, Sheng Han ^b   Zhao, Yanyan ^a   Chen, Ling ^a   Zhang, Ning ^a   Wang, Chun ^a   Guo, Suwan ^a   Wang, Li ^a   Xiao, Hong ^a   Kwan, Justin Y ^c   Wu, Tianxia ^d  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Circadian genes; Depression; Parkinson's disease; Tef

Indexed keywords

CRYPTOCHROME 1; CRYPTOCHROME 2;

ADULT; AGED; ARTICLE; DEPRESSION; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TEF GENE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CRYPTOCHROMES; DEPRESSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 84870378348     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25195     Document Type: Article

References (35)

1. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6: 309-317.
2. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67: 798-801.
3. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151-157.
4. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-189.
5. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 2003: 18: 1250-1256.
6. Marras C, Schüle B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77: 325-333.
7. Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12: 49-52.
8. Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001; 6: 350-352.
9. Burn DJ, Tiangyou W, Allcock LM, Davison J, Chinnery PF. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism Relat Disord 2006; 12: 139-141.
10. Zhang JL, Yang JF, Chan P. No association between polymorphism of serotonin transporter gene and depression in Parkinson's disease in Chinese. Neurosci Lett 2009; 455: 155-158.
11. Soria V, Martínez-Amorós E, Escaramís G, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010; 35: 1279-1289.
12. Kishi T, Yoshimura R, Kitajima T, et al. SIRT1 gene is associated with major depressive disorder in the Japanese population. J Affect Disord 2010; 126: 167-173.
13. Kripke DF, Nievergelt CM, Joo E, Shekhtman T, Kelsoe JR. Circadian polymorphisms associated with affective disorders. J Circadian Rhythms 2009; 7: 2-11.
14. Lavebratt C, Sjöholm LK, Soronen P, et al. CRY2 is associated with depression. PLoS One 2010; 5: e9407.
15. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008; 9: 764-775.
16. Weger BD, Sahinbas M, Otto GW, et al. The light responsive transcriptome of the zebrafish: function and regulation. PLoS One 2011; 6: e17080.
17. Bruguerolle B, Simon N. Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 2002; 25: 194-201.
18. Bunney JN, Potkin SG. Circadian abnormalities, molecular clock genes, and chronobiological treatments in depression. Br Med Bull 2008; 86: 23-32.
19. Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother 2011; 11: 961-970.
20. Fritzsche M, Heller R, Hill H, Kick H. Sleep deprivation as a predictor of response to light therapy in major depression. J Affect Disord 2001; 62: 207-215.
21. Sprouse J, Braselton J, Reynolds L. Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biol Psychiatry 2006; 60: 896-899.
22. Abe M, Herzog ED, Block GD. Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 2000; 11: 3261-3264.
23. Hua P, Liu W, Zhao Y, Ding H, Wang L, Xiao H. Tef polymorphism is associated with sleep disturbances in patients with Parkinson's disease. Sleep Med 2012; 13: 297-300.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
28. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-164.
29. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005; 76: 34-39.
30. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269: 2386-2391.
31. Ke X, Collins A, Ye S. PIRA PCR designer for restriction analysis of single nucleotide polymorphisms. Bioinformatics 2001; 17: 838-839.
32. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98.
33. Gachon F, Fonjallaz P, Damiola F, et al. The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev 2004; 18: 1397-1412.
34. Gavriouchkina D, Fischer S, Ivacevic T, Stolte J, Benes V, Dekens MP. Thyrotroph embryonic factor regulates light-induced transcription of repair genes in zebrafish embryonic cells. PLoS One 2010; 5: e12542.
35. Stranger BE, Forrest MS, Dunning M, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315: 848-853.